Faculty, Staff and Student Publications
Publication Date
10-10-2023
Journal
NPJ Vaccines
Abstract
Human Cytomegalovirus (HCMV) is the leading infectious congenital infection globally and the most common viral infection in transplant recipients, therefore identifying a vaccine for HCMV is a top priority. Humoral immunity is a correlate of protection for HCMV infection. The most effective vaccine tested to date, which achieved 50% reduction in acquisition of HCMV, was comprised of the glycoprotein B protein given with an oil-in-water emulsion adjuvant MF59. We characterize gB-specific monoclonal antibodies isolated from individuals vaccinated with a disabled infectious single cycle (DISC) CMV vaccine, V160, and compare these to the gB-specific monoclonal antibody repertoire isolated from naturally-infected individuals. We find that vaccination with V160 resulted in gB-specific antibodies that bound homogenously to gB expressed on the surface of a cell in contrast to antibodies isolated from natural infection which variably bound to cell-associated gB. Vaccination resulted in a similar breadth of gB-specific antibodies, with binding profile to gB genotypes 1-5 comparable to that of natural infection. Few gB-specific neutralizing antibodies were isolated from V160 vaccinees and fewer antibodies had identifiable gB antigenic domain specificity compared to that of naturally-infected individuals. We also show that glycosylation of gB residue N73 may shield binding of gB-specific antibodies.
Keywords
Immunology, Vaccines
DOI
10.1038/s41541-023-00749-0
PMID
37816743
PMCID
PMC10564777
PubMedCentral® Posted Date
October 2023
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Included in
Allergy and Immunology Commons, Bioinformatics Commons, Biomedical Informatics Commons, Community Health and Preventive Medicine Commons, Influenza Humans Commons, Medical Sciences Commons, Oncology Commons
Comments
Supplementary Material